US Postdocs Grapple with Salary Changes

Postdocs nationwide were set to have an increased minimum salary or become eligible for overtime pay until a court injunction halted new Department of Labor regulations.

Written byKaren Zusi
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

US Department of Labor headquartersWIKIMEDIA, AGNOSTICPREACHERSKIDPostdocs across the country have been on a financial rollercoaster since the end of November. In order to be compliant with new federal regulations from the US Department of Labor under the Fair Labor Standards Act (FLSA), universities and institutions nationwide were required to raise postdoctoral researchers’ salaries to a $47,476 minimum, or start paying overtime wages to those working more than 40 hours per week. The regulations were set to be required on the first of this month. But a court injunction, granted after 21 states filed against the regulations, halted the process on November 22.

Many universities had already announced salary updates for postdocs. Some institutions, such as Miami University in Ohio, elected to start tracking hours. Administrations sent out new contracts and offered principal investigators (PIs) temporary “bridge” funding to support the salary increases. But when news of the injunction broke, many of these offices put their plans on hold. “A lot of us felt like we were being told we didn't matter,” said Jennifer Riehl, a postdoc in the entomology department at the University of Wisconsin-Madison (UW-Madison). “It makes you ask, ‘Why am I doing this? What is the benefit, especially with the [poor] outlook for being able to continue in academia?’”

“It’s very easy for postdocs to fall through the cracks,” said Gary McDowell, executive director of ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies